Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
U.K. Start-Up Gets Cash Injection
by Alex Scott
August 12, 2013
| A version of this story appeared in
Volume 91, Issue 32
TVM Life Science Ventures, a Montreal-based venture capital firm, has invested in Ixchelsis. A British start-up, Ixchelsis plans to use the funds to take IX-01, an oxytocin antagonist for treating premature ejaculation, to proof-of-concept stage. Ixchelsis was founded in 2011 by former Pfizer executive Gary Muirhead following the pharma giant’s closure of most of its R&D site in Sandwich, England. Three other former Pfizer scientists also work for Ixchelsis. IX-01 was discovered by Pfizer.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter